Innoviva, Inc. - Common Stock (NQ:INVA)

23.48 -0.76 (-3.16%)

Streaming Delayed Price Updated: 12:55 PM EST, Feb 26, 2026 Add to My Watchlist

Price and Volume

Volume	426,046
Open	25.00
Bid (Size)	23.45 (100)
Ask (Size)	23.50 (200)
Prev. Close	24.24
Today's Range	23.48 - 25.14
52wk Range	16.52 - 24.25
Shares Outstanding	65,504,384
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

February 25, 2026

From Innoviva, Inc.

Via Business Wire

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

From Innoviva, Inc.

Via Business Wire

Performance

YTD	+18.1%	+18.1%
1 Month	+20.3%	+20.3%
3 Month	+8.1%	+8.1%
6 Month	+18.3%	+18.3%
1 Year	+30.2%	+30.2%

More News

Innoviva Inc (NASDAQ:INVA) Presents a Compelling Value Investment Case ↗

February 10, 2026

Via Chartmill

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗

January 08, 2026

Via MarketBeat

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

December 16, 2025

Via Chartmill

Beyond The Numbers: 5 Analysts Discuss Innoviva Stock ↗

September 30, 2025

Via Benzinga

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

December 12, 2025

From Innoviva, Inc.

Via Business Wire

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

December 11, 2025

From Innoviva, Inc.

Via Business Wire

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

November 25, 2025

From Innoviva, Inc.

Via Business Wire

Stay updated with the stocks that are on the move in today's pre-market session. ↗

November 13, 2025

Via Chartmill

Value Investing Case Study: INNOVIVA INC (NASDAQ:INVA) ↗

November 11, 2025

Via Chartmill

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

November 05, 2025

From Innoviva, Inc.

Via Business Wire

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

October 20, 2025

From Innoviva Specialty Therapeutics

Via Business Wire

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

October 07, 2025

From Innoviva Specialty Therapeutics

Via Business Wire

Innoviva Inc (NASDAQ:INVA): A Prime Candidate for Value Investors Seeking Undervalued Stocks ↗

September 08, 2025

Via Chartmill

Innoviva to Participate in Upcoming Investor Conferences

August 26, 2025

From Innoviva, Inc.

Via Business Wire

Innoviva Inc (NASDAQ:INVA) Recognized as a "Decent Value" Stock with Strong Valuation and Growth Potential ↗

August 18, 2025

Via Chartmill

Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

August 13, 2025

From Innoviva Specialty Therapeutics, Inc.

Via Business Wire

Expert Outlook: Innoviva Through The Eyes Of 4 Analysts ↗

August 11, 2025

Via Benzinga

This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday ↗

August 11, 2025

Via Benzinga

Innoviva (INVA) Q2 Sales Jump 64% ↗

August 06, 2025

Via The Motley Fool

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

August 06, 2025

From Innoviva, Inc.

Via Business Wire

This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

July 14, 2025

Via Benzinga

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

June 12, 2025

From Innoviva Specialty Therapeutics, Inc.

Via Business Wire

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

June 10, 2025

From Innoviva, Inc.

Via Business Wire

Frequently Asked Questions

Is Innoviva, Inc. - Common Stock publicly traded?

Yes, Innoviva, Inc. - Common Stock is publicly traded.

What exchange does Innoviva, Inc. - Common Stock trade on?

Innoviva, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Innoviva, Inc. - Common Stock?

The ticker symbol for Innoviva, Inc. - Common Stock is INVA on the Nasdaq Stock Market

What is the current price of Innoviva, Inc. - Common Stock?

The current price of Innoviva, Inc. - Common Stock is 23.48

When was Innoviva, Inc. - Common Stock last traded?

The last trade of Innoviva, Inc. - Common Stock was at 02/26/26 12:55 PM ET

What is the market capitalization of Innoviva, Inc. - Common Stock?

The market capitalization of Innoviva, Inc. - Common Stock is 1.54B

How many shares of Innoviva, Inc. - Common Stock are outstanding?

Innoviva, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.